ICPT - Intercept Pharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc.
305 Madison Avenue
Morristown, NJ 07960
United States
646 747 1000
https://www.interceptpharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 341
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Mr. Jerome B. Durso | Pres, CEO & Director | 1.37M | N/A | 1968 |
| Mr. Andrew Saik | Chief Financial Officer | 888.6k | N/A | 1969 |
| Mr. Jared M. Freedberg J.D. | Gen. Counsel | 812.55k | N/A | 1968 |
| Ms. Linda M. Richardson | Exec. VP & Chief Commercial Officer | 837.73k | N/A | 1964 |
| Dr. M. Michelle Berrey M.D., M.P.H., MPH. | Pres of R&D and Chief Medical Officer | 1.12M | N/A | 1967 |
| Mr. Rocco Venezia | Chief Accounting Officer & Treasurer | N/A | N/A | 1976 |
| Mr. Nareg Sagherian | Exec. Director of Global Investor Relations | N/A | N/A | N/A |
| Mr. David Ford | Chief HR Officer | N/A | N/A | 1970 |
| Dr. Mark Pruzanski M.D. | Founder, Advisor & Director | N/A | N/A | 1968 |
| Paul Nitschmann | Sr. VP of Regulatory Affairs | N/A | N/A | N/A |
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey.
Corporate governance
Intercept Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 June 2023 is 5. The pillar scores are Audit: 8; Board: 3; Shareholder rights: 6; Compensation: 3.
